Please provide your email address to receive an email when new articles are posted on . Older patients with atrial fibrillation were more likely to have high bleeding risk contraindications with oral ...

Please provide your email address to receive an email when new articles are posted on . An analysis of the ongoing SAGE-AF trial revealed that approximately 23% of geriatric patients with atrial ...

It is uncommon for hospitalized older adults newly diagnosed with atrial fibrillation to start anticoagulation therapy. In fact, only about 25% overall begin taking these medications soon after ...

Most patients with pulmonary embolism (i.e., low-risk, intermediate–low-risk, and most intermediate–high-risk) are adequately managed with anticoagulation alone. Selected intermediate–high-risk ...

Anticoagulant or antiplatelet drugs, sometimes called blood thinners, help prevent blood clots. There are many options, including heparin and warfarin. Preventing clots reduces the risk of stroke and ...

Atrial fibrillation (AF) is a major risk factor for disabling ischemic strokes. Anticoagulation is highly effective for stroke prevention in patients with AF, but a substantial number of patients are ...

HealthDay News — Clinical practice guidelines for anticoagulation therapy for cardiopulmonary bypass (CPB) have been developed and were published in the February issue of the Annals of Thoracic ...

With more than 15 years of evidence and the continuing evolution of devices, the Society for Cardiovascular Angiography and Interventions (SCAI) and the Heart Rhythm Society (HRS) have released ...

African-American patients with A-fib are less likely to receive direct oral anticoagulants (DOACs) and tend to have poorer control on warfarin compared with their white counterparts, a registry study ...

To read this article for CME, click here. August 9, 2007 — Results of the Birmingham Atrial Fibrillation Treatment of the Aged (BAFTA) trial show that among patients over age 75 years with atrial ...

Data from First Phase I Study of Antidote for Pradaxa® (dabigatran etexilate mesylate) Presented at American Heart Association Scientific Sessions Data indicate the antidote may be able to achieve ...